In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Merck acquires Peloton for up to $2.2bn

Executive Summary

Merck & Co. Inc. will pay $1.05bn in cash up front to acquire privately held cancer drug developer Peloton Therapeutics Inc. The deal also includes up to $1.15bn in earn-outs based on regulatory and sales achievements.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Acquisition of Private Biotech
    • Payment Includes Cash
    • Includes Earnout

Related Companies

UsernamePublicRestriction

Register